Objective:
To explore the motivations and actions taken by ten23 Health towards sustainability in the pharmaceutical industry.
Approach:
- Background in Science: The interviewee's interest in science began with a chemistry teacher, leading to a career in pharmacy and industry roles at Merck, Roche, and Lonza.
- Entrepreneurial Spirit: The desire to create and develop organizations led to the founding of ten23 Health, focusing on sustainability.
- Sustainability Focus: The interviewee highlights the need for the pharmaceutical industry to address its environmental impact, particularly regarding carbon emissions.
- Investor Engagement: Despite initial concerns, investors at 3i support the sustainability approach, leading to initiatives like plastic offsetting.
- Organizational Design: Sustainability is integrated into every aspect of ten23 Health's operations, including energy and water consumption monitoring.
- Innovative Practices: The company is exploring bioplastics and collaborating with AI for life cycle assessments to improve sustainability in manufacturing.
Key Findings:
- The pharmaceutical sector created more than 50 megatons of carbon dioxide emissions in 2015, which, per revenue, is more than the automotive sector.
- Sustainability practices at ten23 Health include using 100% natural energy sources and local, Fairtrade coffee.
- The company aims to innovate in product design with environmental considerations alongside regulatory compliance.
Interpretation:
Limitations:
- The discussion lacks specific quantitative data on sustainability outcomes.
- There is no mention of challenges faced in implementing sustainability measures.
Conclusion:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
